<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>nyserelease.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>

PRESS RELEASE                           LIFE SCIENCES RESEARCH, INC.
                                        (OTCBB: LSRI)

                                        PO Box 2360
                                        Mettlers Road
                                        East Millstone, NJ 08875-2360

                                        For Further Information:
                                        Richard Michaelson
                                        Phone:   US: (732) 649-9961
                                        e-mail: LifeSciencesResearch@LSRinc.net


August 22, 2005

                   LSR TO LIST ON THE NEW YORK STOCK EXCHANGE

East  Millstone,  New Jersey,  August 22, 2005 - Life  Sciences  Research,  Inc.
(OTCBB:  LSRI) announced today that its listing application has been accepted by
the New York Stock Exchange (NYSE).  Trading is expected to begin on the NYSE on
Wednesday, September 7, 2005 under the new ticker symbol "LSR". Until that time,
LSR will continue to trade on the Nasdaq OTCBB.

Andrew Baker, the Company's Chairman and Chief Executive Officer,  stated, "This
move to the world's most prestigious stock exchange marks an important milestone
for LSR. The growing visibility LSR has enjoyed in the investment  community has
played an important  part in our  qualifying for the NYSE. We are confident that
this listing will provide us with improved liquidity through access to a broader
domestic and worldwide investor base."

Brian  Cass,  LSR's  President,  added  "It is  gratifying  that  the  Company's
significant growth in revenues, earnings and market capitalization over the past
several years has enabled us to achieve this important objective.  As one of the
founders and leaders in the market for outsourced  safety  testing  services for
the world's  pharmaceutical and biotech  industries,  LSR is pleased to join the
many life sciences companies already listed on the NYSE."

"On  behalf of my  colleagues  at the New York Stock  Exchange,  I would like to
welcome Life  Sciences  Research to the NYSE family of listed  companies,"  said
Exchange  President  and co-COO  Catherine  R.  Kinney.  "We look forward to our
partnership  with  Life  Sciences  Research  and its  shareholders,  along  with
providing a  marketplace  of the highest  quality and  renowned for its superior
reach and visibility to the global investment community."

Life Sciences  Research is a global  contract  research  organization  providing
product   development   services  to  the   pharmaceutical,   agrochemical   and
biotechnology  industries.  LSR brings  leading  technology  and  capability  to
support its clients in  non-clinical  safety  testing of new  compounds in early
stage development and assessment.  The purpose of this work is to identify risks
to humans, animals or the environment resulting from the use or manufacture of a
wide  range of  chemicals  which  are  essential  components  of LSR's  clients'
products.   The  Company's   services  are  designed  to  meet  the   regulatory
requirements of governments  around the world. LSR operates research  facilities
in the United States (the Princeton  Research Center, New Jersey) and the United
Kingdom (Huntingdon and Eye, England).

This announcement  contains statements that may be forward-looking as defined by
the Private Securities Litigation Reform Act of 1995. These statements are based
largely  on  LSR's  expectations  and are  subject  to a  number  of  risks  and
uncertainties,  certain  of  which  are  beyond  LSR's  control,  as more  fully
described in the Company's  SEC filings,  including its Form 10-K for the fiscal
year ended  December  31,  2004,  as filed with the US  Securities  and Exchange
Commission.


                                   --- end ---

</TEXT>
</DOCUMENT>